Patients with well-compensated NASH cirrhosis and three metabolic risk factors were selected for inclusion in the study.

Oppenheimer lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $350 from $375 and keeps an Outperform rating on the ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $203.59.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

Cantor Fitzgerald reiterated their neutral rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced that it will release its third-quarter 2024 ...

Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and ...

The Janus Henderson Biotech Innovation Fund continues to lead all biopharma and life sciences hedge funds after mixed results for the general strategy in September. Several funds lost money last month ...

As of June 30, 2024, Paulson held 1.85 million shares of Madrigal Pharmaceuticals, which would currently be worth around $386 million as of the time of writing. This position is a significant one ...

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8 th Annual ...